Overall Survival in Patients with Mucinous Carcinoma of Breast: A Population-Based Study

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Budzik MP, Fudalej MM, Badowska-Kozakiewicz AM. Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type. Sci Rep. 2021;11(1):5770. doi:10.1038/s41598-021-85309-z
   PubMed Web of Science ®Google Scholar
• Yu P, Liu P, Zou Y, et al. Breast-conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: a SEER population-based study. Cancer Med. 2020;9(15):5381–5391. doi:10.1002/cam4.3202
   PubMed Web of Science ®Google Scholar
• Guo R, Chen B, Erickson LA. Mucinous carcinoma of the breast. Mayo Clin Proc. 2020;95(9):2049–2050. doi:10.1016/j.mayocp.2020.07.008
   PubMed Web of Science ®Google Scholar
• Harrison BT, Dillon DA. An update of mucinous lesions of the breast. Surg Pathol Clin. 2018;11(1):61–90. doi:10.1016/j.path.2017.09.002
   PubMedGoogle Scholar
• Risner V, Jordan S. Mucinous carcinoma in an octogenarian: treatment and management of breast cancer in the elderly. Radiol Case Rep. 2021;16(11):3201–3207. doi:10.1016/j.radcr.2021.07.077
   PubMedGoogle Scholar
• Limaiem F, Ahmad F. Mucinous Breast Carcinoma. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Alothman S, Saeed S, Khan K, Ramcharan A, DePaz H. Giant mucinous carcinoma of the breast. Cureus. 2018;10(11):e3606. doi:10.7759/cureus.3606
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Rose C, Hilkens J, Hilgers J. Detection of surface antigens defined by monoclonal antibodies in primary mucinous breast carcinomas. Relation to prognostic factors and recurrence-free survival. Virchows Arch a Pathol Anat Histopathol. 1986;409(4):497–505. doi:10.1007/BF00705420
   PubMedGoogle Scholar
• Skotnicki P, Sas-Korczynska B, Strzepek L, et al. Pure and mixed mucinous carcinoma of the breast: a comparison of clinical outcomes and treatment results. Breast J. 2016;22(5):529–534. doi:10.1111/tbj.12621
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Xu X, Bi R, Shui R, et al. Micropapillary pattern in pure mucinous carcinoma of the breast - does it matter or not? Histopathology. 2019;74(2):248–255. doi:10.1111/his.13722
   PubMed Web of Science ®Google Scholar
• Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–547. doi:10.1007/s10549-007-9809-z
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344. doi:10.1111/j.0006-341X.2000.00337.x
   PubMed Web of Science ®Google Scholar
• Zhang L, Jia N, Han L, Yang L, Xu W, Chen W. Comparative analysis of imaging and pathology features of mucinous carcinoma of the breast. Clin Breast Cancer. 2015;15(2):e147–e154. doi:10.1016/j.clbc.2014.11.005
   PubMed Web of Science ®Google Scholar
• de Boer AZ, Bastiaannet E, Putter H, et al. Prediction of other-cause mortality in older patients with breast cancer using comorbidity. Cancers. 2021;13(7):1627.
   PubMed Web of Science ®Google Scholar
• Bergman L, Dekker G, van Kerkhoff EH, Peterse HL, van Dongen JA, van Leeuwen FE. Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. Breast Cancer Res Treat. 1991;18(3):189–198. doi:10.1007/BF01990035
   PubMed Web of Science ®Google Scholar
• Turashvili G, Brogi E, Morrow M, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Res Treat. 2017;165(1):65–76. doi:10.1007/s10549-017-4326-1
   PubMed Web of Science ®Google Scholar
• Zulauf N, Bruggmann D, Groneberg D, Oremek GM. Expressiveness of bone markers in breast cancer with bone metastases. Oncology. 2019;97(4):236–244. doi:10.1159/000500675
   PubMed Web of Science ®Google Scholar
• He F, Chiou AE, Loh HC, et al. Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114(40):10542–10547. doi:10.1073/pnas.1708161114
   PubMed Web of Science ®Google Scholar
• Louwman MWJ, Vriezen M, van Beek MWPM, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121(1):127–135. doi:10.1002/ijc.22625
   PubMed Web of Science ®Google Scholar
• Andre S, Cunha F, Bernardo M, Meneses e Sousa J, Cortez F, Soares J. Mucinous carcinoma of the breast: a pathologic study of 82 cases. J Surg Oncol. 1995;58(3):162–167. doi:10.1002/jso.2930580305
   PubMed Web of Science ®Google Scholar
• Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat. 1991;18(1):27–32. doi:10.1007/BF01975440
   PubMed Web of Science ®Google Scholar
• Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77(2):336–340. doi:10.1038/bjc.1998.52
   PubMed Web of Science ®Google Scholar
• Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59(3):271–278. doi:10.1023/A:1006308619659
   PubMed Web of Science ®Google Scholar
• Marrazzo E, Frusone F, Milana F, et al. Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020;49:87–92. doi:10.1016/j.breast.2019.11.002
   PubMed Web of Science ®Google Scholar
• Wu SG, Li FY, Wang J, Lian CL, Zhou J, He ZY. Omission of adjuvant radiotherapy following breast-conserving surgery for elderly women with early-stage pure mucinous breast carcinoma. Radiat Oncol. 2019;14(1):190. doi:10.1186/s13014-019-1394-x
   PubMed Web of Science ®Google Scholar
• Fu J, Wu L, Jiang M, et al. Clinical nomogram for predicting survival outcomes in early mucinous breast cancer. PLoS One. 2016;11(10):e0164921. doi:10.1371/journal.pone.0164921
   PubMed Web of Science ®Google Scholar
• Gwark SC, Lee HS, Lee Y, et al. Clinical implication of HER2 status in hormone receptor-positive mucinous breast cancer. Ann Surg Oncol. 2019;26(7):2166–2174. doi:10.1245/s10434-019-07332-9
   PubMed Web of Science ®Google Scholar